Ab­bisko signs $70M up­front deal with Mer­ck KGaA for PhI­II can­cer drug

Shang­hai-based Ab­bisko Ther­a­peu­tics has lined up an­oth­er part­ner for its on­col­o­gy pipeline and will re­ceive $70 mil­lion up­front as Mer­ck KGaA grabs com­mer­cial­iza­tion rights to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER